Noventure has announced that it has signed an exclusivity agreement for the licensing of the innovative food supplement EPA3G, with global partner Azur – a division of Solutex (Madrid, Spain).
Within the marketplace, there is a huge offering in omega-3 supplements. There is much debate on the amount of omega-3 required to deliver meaningful health benefits and on what is a realistic dosage to suit everyday lifestyles. The current options of multiple servings, or those bulky, difficult-to-swallow capsules, are not ideal.
EPA3G successfully fills this market gap. With almost three grams of pure EPA (eicosapentaenoic acid) in one easy-to-take daily dose, EPA3G is a patented, state-of-the-art drinkable emulsion available in sachets, with excellent texture, taste and scent.
Under the terms of the agreement, Noventure has the right to license EPA3G to specialized companies. This must-have marketing expertise and knowledge in the commercialization of high-end food supplements. The agreement covers over 50 countries on different continents, including all EU members and associated states, the UK, the Balkans, Russia, Ukraine, Eurasian countries, Mexico, Taiwan, and several African states. The financial terms of the agreement have not been disclosed.